Skip to main content
. 2013 Dec;15(12):1354–1362. doi: 10.1593/neo.131660

Figure 6.

Figure 6

Pharmacological inhibition of RSK3 acts synergistically with erlotinib. BxPC-3 (A) and PaTu-8988t (B) cells were treated with the RSK inhibitor BI-D1870 in the presence or absence of erlotinib for 48 hours. Cell viability of cells was assessed using MTT assays. Results are representative for three independent experiments. *P < .05 compared to erlotinib only and to erlotinib + BI-D (1 µM, A or 5 µM, B).